Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Factors contributing to the decline in profit included lower revenue from the highly profitable pharmaceutical marketing support business, the absence of contributions from relatively highly profitable and large-scale projects recorded in the previous year’s first quarter, lower revenue from recruitment and job-seeker support services, higher upfront investment costs for new openings, and upfront investment overseas. Meanwhile, revenue growth was supported by steady performance in the medical institution and hospice businesses, new CS Set contract wins, and foreign exchange effects from the trend toward a weaker yen.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥90,105 million (YoY +4.5%) |
| Operating profit | ¥18,077 million (YoY -8.6%) |
| Ordinary income | ¥18,641 million (profit before tax) (YoY -5.3%) |
| Profit attributable to owners of the parent | ¥9,074 million (YoY -23.4%) |
| Net income per share | ¥13.60 |
| Equity ratio | End of the current fiscal period 64 / End of previous period 64 |
| Total assets | ¥634,803 million |
| Net assets | ¥443,629 million (total equity) |
| Cash and cash equivalents at end of period | ¥162,174 million |
| Full-year earnings forecast | Net Sales ¥400,000 million (YoY +13.8%) / Operating profit ¥80,000 million (YoY +8.8%) / Ordinary income ¥81,000 million (profit before tax) (YoY +6.2%) / Net income 56,000 Millions of yen (profit for the period) (YoY +3.6%) / Profit for the period attributable to owners of the parent ¥53,000 million (YoY +7.9%) |
| Annual Dividend Forecast | ¥22 → To be determined（To be determined） |
| Segment revenue | Medical Platform ¥25,585 million (YoY +1.2%), Evidence Solutions ¥5,691 million (YoY -8.5%), Career Solutions ¥7,999 million (YoY -3.4%), Site Solutions ¥14,159 million (YoY +9.0%), Patient Solutions ¥14,752 million (YoY +9.9%), Overseas expansion ¥22,748 million (YoY +9.8%) |
| Segment profit | Medical Platform ¥8,872 million (YoY -1.2%), Evidence Solutions ¥879 million (YoY -33.1%), Career Solutions ¥3,597 million (YoY -1.8%), Site Solutions ¥15 million (YoY -97.9%), Patient Solutions ¥750 million (YoY +66.2%), Overseas expansion ¥4,615 million (YoY -4.9%) |
| Depreciation and amortization | ¥4,346 million (depreciation and amortization) |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 679,124,800 shares |
| Treasury Shares at Period-End | 11,695,139 shares |
| Factors Behind Changes in Business Performance | Factors contributing to the decline in profit included lower revenue from the highly profitable pharmaceutical marketing support business, the absence of contributions from relatively highly profitable and large-scale projects recorded in the previous year’s first quarter, lower revenue from recruitment and job-seeker support services, higher upfront investment costs for new openings, and upfront investment overseas. Meanwhile, revenue growth was supported by steady performance in the medical institution and hospice businesses, new CS Set contract wins, and foreign exchange effects from the trend toward a weaker yen. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Profit was weighed down by lower revenue from the highly profitable pharmaceutical marketing support business, the absence of contributions from highly profitable, large-scale projects recorded in the previous year’s first quarter, higher upfront investment costs for new openings in the U.S. business and home-visit nursing business, and upfront investment overseas. Meanwhile, revenue was supported by the medical institution and hospice businesses, new CS Set contract wins, and foreign exchange effects from the weaker yen.